News Daily News Transthyretin Cardiac Amyloidosis a Common Cause of HF in Older Black Patients Todd Neale September 12, 2025
News Daily News Dual Approach the Best Remedy for Aortic Stenosis, Amyloidosis: Registry Caitlin E. Cox June 09, 2025
News Conference News ESC Heart Failure 2025 HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM Todd Neale May 19, 2025
News Daily News Acoramidis Approved in Europe for ATTR Cardiomyopathy Michael O'Riordan February 12, 2025
News Daily News FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy L.A. McKeown November 25, 2024
News Conference News ESC 2024 HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM L.A. McKeown August 30, 2024
News Daily News Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B Michael O'Riordan June 24, 2024
News Daily News FDA Decides Not to Approve Patisiran in ATTR Cardiomyopathy L.A. McKeown October 10, 2023
News Conference News ESC 2023 More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM Michael O'Riordan August 31, 2023
News Daily News Carpal Tunnel Syndrome Again Tied to Heart Failure: German Data Caitlin E. Cox July 19, 2023
News Conference News ESC Heart Failure 2023 Amyloid Removal Looks Possible in ATTR Cardiomyopathy Imaging Trial Shelley Wood May 23, 2023
News Conference News AHA 2022 CRISPR/Cas-9 Gene Editing Shows Promise in Transthyretin Amyloidosis Yael L. Maxwell November 05, 2022
News Daily News As Amyloidosis Field Explodes, Physicians Need to Spot and Treat Todd Neale October 20, 2021
News Conference News AHA, Editors, and Cardiologists Ask: How Did ‘Racist’ Paper Make It to Print? Michael O'Riordan August 05, 2020
News Industry News CeleCor Therapeutics Announces Positive First-in-Human Data of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor, Presented at TCT 2019 September 25, 2019
News Daily News Gut Bacteria-Produced Compound May Help Identify Atherosclerotic Burden in Patients With CAD Todd Neale June 01, 2016
News Industry News Vessix Vascular to Present 3-Month, 6-Month Results From REDUCE-HTN Renal Denervation Clinical Study at TCT October 22, 2012
News Daily News TRIAS HR Published: Genous Stent Doubles Target Lesion Failure Leah Lawrence August 23, 2011